Who is sponsoring NCT03007225?

NCT03007225 is sponsored by Ain Shams University.

What drugs are being tested in NCT03007225?

Interventions in NCT03007225: Trans-arterial chemoembolization (TACE), TACE with Drug Eluting Beads procedure.

What condition does NCT03007225 study?

NCT03007225 studies HepatoCellular Carcinoma.

Is NCT03007225 still recruiting?

NCT03007225 is currently completed. Last updated 27 September 2020.

Are results published for NCT03007225?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-09-27 · How we verify

NCT03007225

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients

Completed Phase 4 Results posted Last updated 27 September 2020

What this trial tests

Phase 4 trial testing Trans-arterial chemoembolization (TACE) in HepatoCellular Carcinoma in 50 participants. Completed in 1 August 2016.

Timeline

1 July 2015

Primary endpoint
1 August 2016

1 August 2016

Quick facts

Lead sponsor	Ain Shams University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 July 2015
Primary completion	1 August 2016
Estimated completion	1 August 2016

Drugs / interventions tested

Trans-arterial chemoembolization (TACE) — full drug profile →
TACE with Drug Eluting Beads procedure — full drug profile →

Conditions studied

HepatoCellular Carcinoma — all drugs for HepatoCellular Carcinoma →

Sponsor

Ain Shams University

Who can join

Adults 18 to 65, male only, with HepatoCellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants With Complete Response
Time frame: 1 year
Assessment of Radiological response by modified RECIST radiological criteria after treatment (Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.")

Sponsor's own description

This study aimed to to compare the conventional transarterial chemoembolization (cTACE) with chemoembolization using doxorubicin drug eluting beads (DEB-TACE) for the treatment of hepatocellular carcinoma regarding short term efficacy and safety in first 3 months after embolization

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Trans-arterial chemoembolization (TACE)

Trials testing the same drug.

NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting

Other recruiting trials for HepatoCellular Carcinoma

Currently open trials in the same condition.

NCT03033446 — Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma · Phase 2 · active not recruiting

Other Ain Shams University trials

Trials by the same sponsor.

NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03007225 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
Last refreshed: 27 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03007225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing